健民集团(600976) - 2024 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 0.04% to ¥99,523,950.19[15] - Operating revenue decreased by 4.27% to ¥970,121,135.45[15] - Basic and diluted earnings per share remained at ¥0.65[15] - The net profit for the first quarter of 2024 was CNY 100,197,440.85, slightly up from CNY 99,813,628.68 in the same period last year[53] - Total comprehensive income attributable to the parent company was $99,523,950.19, slightly down from $99,560,117.11 year-over-year[64] - Total comprehensive income for minority shareholders was $673,490.66, up from $253,511.57, indicating improved performance for minority interests[64] Cash Flow - Net cash flow from operating activities decreased by 22.73% to -¥51,647,096.25[15] - The company reported a decrease in cash flow from operating activities, indicating potential liquidity challenges[15] - The net cash flow from operating activities increased by 22.73% due to higher government subsidies received compared to the previous period[44] - Net cash flow from operating activities was -$51,647,096.25, an improvement from -$66,838,774.27 in the previous period, indicating a reduction in cash outflow[62] - Total cash inflow from investment activities was $342,401,724.55, down from $500,845,717.94, reflecting a decrease in investment returns[62] - Cash received from other operating activities increased to $68,933,164.39 from $43,465,359.89, indicating growth in operational cash inflows[62] - Total cash outflow from operating activities was $1,016,786,274.66, compared to $892,877,476.86 in the previous period, reflecting increased operational expenses[62] Assets and Liabilities - Total assets increased by 3.97% to ¥4,333,569,107.70 compared to the previous year[4] - Total assets as of the reporting date were ¥4,333,569,107.70, an increase from ¥4,167,951,216.96[22] - Non-current assets totaled ¥1,467,405,743.16, up from ¥1,402,059,319.47, indicating a growth of 4.7%[22] - Current liabilities amounted to ¥1,903,772,719.94, compared to ¥1,856,942,135.52 in the previous year, reflecting an increase of 2.5%[37] - Total liabilities were ¥1,976,053,809.23, up from ¥1,911,466,639.41, marking a rise of 3.4%[37] - The total liabilities and equity increased to CNY 4,333,569,107.70 from CNY 4,167,951,216.96 year-over-year[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,938[18] - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 24.13% of shares[18] - The total equity attributable to shareholders of the parent company increased to CNY 2,348,063,298.55 from CNY 2,247,706,068.29 year-over-year[50] Investment and Expenses - Research and development expenses increased to ¥22,951,668.26 in Q1 2024, up 28.5% from ¥17,823,901.34 in Q1 2023[25] - Investment income for Q1 2024 was ¥59,774,640.71, compared to ¥44,001,851.68 in Q1 2023, representing a growth of 35.9%[25] - The investment income from joint ventures and associates rose to CNY 60,619,066.69, compared to CNY 44,726,245.20 in the previous year[53] - The company reported a decrease in other operating income and expenses, with a net loss of CNY 672,659.88[48] - Cash inflow from investment income decreased significantly to $2,332,844.05 from $96,327,867.94, indicating a decline in investment performance[62] - Cash outflow for other investment activities was $280,000,000.00, down from $330,000,000.00, suggesting a reduction in investment expenditures[62]